Title : Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.

Pub. Date : 2018 Mar 1

PMID : 28379536






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Background: In TEMPO 3:4, the vasopressin V2 receptor antagonist tolvaptan slowed total kidney volume (TKV) growth and estimated glomerular filtration rate (eGFR) decline relative to placebo. Tolvaptan arginine vasopressin receptor 2 Homo sapiens